Recent developments on dry eye disease treatment compounds

Saudi Journal of Ophthalmology

Volumn 28, Issue 1, 2014, Pages 19-30

  Colligris, Basilio ^a   Alkozi, Hanan Awad ^a   Pintor, Jesus ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Anti inflammatory; Dry eye; Keratitis sicca; Keratoconjunctivitis sicca; Mucin secretion; NSAID; Tear secretion; Xerophthalmia

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; CALCINEURIN INHIBITOR; CALCIUM ACTIVATED CHLORIDE CHANNEL; CYCLOHEPTATHIOPHENE; CYTOKINE RECEPTOR ANTAGONIST; KETOROLAC TROMETAMOL; LACRITIN PEPTIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PROTEIN INHIBITOR; PROTEIN KINASE ZAP 70; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; VOCLOSPORIN;

ARTICLE; DRUG STRUCTURE; DRY EYE; EYE INFLAMMATION; PATENT; PRIORITY JOURNAL; RNA INTERFERENCE; TEAR FILM; TREATMENT INDICATION;

EID: 84893810985     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2013.12.003     Document Type: Article

References (89)

1. Viso E., Rodriguez-Ares M.T., Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol 2009, 16(1):15-21.
2. Moss S.E., Klein R., Klein B.E. Long-term incidence of dry eye in an older population. Optom Vis Sci 2008, 85(8):668-674.
3. Barker K.E., Savage N.W. Burning mouth syndrome: an update on recent findings. Aust Dent J 2005, 50(4):220-223. quiz 88.
4. Leiblum S.R., Hayes R.D., Wanser R.A., et al. Vaginal dryness: a comparison of prevalence and interventions in 11 countries. J Sex Med 2009, 6(9):2425-2433.
5. Dartt D.A. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res 2009, 28(3):155-177.
6. Acosta M.C., Peral A., Luna C., et al. Tear secretion induced by selective stimulation of corneal and conjunctival sensory nerve fibers. Invest Ophthalmol Vis Sci 2004, 45(7):2333-2336.
7. Belmonte C., Aracil A., Acosta M.C., et al. Nerves and sensations from the eye surface. Ocul Surf 2004, 2(4):248-253.
8. Albietz J.M., Bruce A.S. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001, 22(1):8-18.
9. Yaguchi S., Ogawa Y., Kamoi M., et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transplant 2012, 47(11):1465-1469.
10. Korb D.R., Greiner J.V., Glonek T., et al. Effect of periocular humidity on the tear film lipid layer. Cornea 1996, 15(2):129-134.
11. Methodologies to diagnose and monitor dry eye disease 2007 Report of the international dry eye workshop. Ocul Surf 2007, 5(2):108-152.
12. Luo L., Li D.Q., Corrales R.M., et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Cont Lens 2005, 31(5):186-193.
13. Luo L., Li D.Q., Doshi A., et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis sci 2004, 45(12):4293-4301.
14. Yang C.Q., Sun W., Gu Y.S. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B 2006, 7(8):675-678.
15. Bowling E, Russell GE. Topical Steroids and the treatment of dry eye.2011. http://www.reviewofcontactlenses.com/content/d/dry_eye/c/27245/.
16. Allergan. RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%. http://www.allergan.com/products/eye_care/restasis.htm2012.
17. Caceres V. Ocular surface, treating dry eye. http://www.eyeworld.org/article-treating-dry-eye2011.
18. Laurence A., Pesu M., Silvennoinen O., et al. JAK kinases in health and disease: an update. Open Rheumatol J 2012, 6:232-244.
19. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (New York, NY) 1994, 264(5164):1415-1421.
20. Leonard W.J., Lin J.X. Cytokine receptor signaling pathways. J Allergy Clin Immunol 2000, 105(5):877-888.
21. Scott M.J., Godshall C.J., Cheadle W.G. Jaks, STATs, cytokines, and sepsis. Clin Diagn Lab Immunol 2002, 9(6):1153-1159.
22. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Invest Drugs (London, England: 2000) 2009, 10(5):491-504.
23. Hirota K., Duarte J.H., Veldhoen M., et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011, 12(3):255-263.
24. Kang M.H., Kim M.K., Lee H.J., et al. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci 2011, 26(7):938-944.
25. Brocker C., Thompson D., Matsumoto A., et al. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 2010, 5(1):30-55.
26. Barabino S., Shen L., Chen L., et al. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005, 46(8):2766-2771.
27. Garcia CK, Reddy S, Sieczkiewicz GJ, et al., IL-17 family cytokine compositions and uses, WO/2011/0445632011.
28. Adelman BA, Treating surface of the eye disorders. WO/2011/1634522011.
29. Kang SW, Cim CH, Composition for prevention or treatment of eye diseases, WO/2010/0475002010.
30. MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase). In: , editor. National Center for Biotechnology Information (NCBI)2013. http://www.ncbi.nlm.nih.gov/gene?Db=gene%26Cmd=ShowDetailView%26TermToSearch=4318.
31. Sisto M., Lisi S., Lofrumento D.D., et al. Sjogren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-kappaB. Genes Immun 2012, 13(5):411-420.
32. Hong BS, Meadows DL, Methods and compositions for treating dry eye. WO/2009/0649832009.
33. Nagelhout T.J., Gamache D.A., Roberts L., et al. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J Ocul Pharmacol Ther 2005, 21(2):139-148.
34. Sambursky R., O'Brien T.P. MMP-9 and the perioperative management of LASIK surgery. Curr Opin Ophthalmol 2011, 22(4):294-303.
35. Rodgers JD, Shepard S, Li YL, et al., Azetidine and cyclobutane derivatives as JAK inhibitors. WO/2009/1145122009.
36. Friedman PA, Friedman JS, Luchi ME, et al., Janus kinase inhibitors for treatment of dry eye and other eye related diseases, US200611637545, WO/2010/039939, US201001134162010.
37. Rodgers JD, Shepard S, Azetidine and cyclobutane derivatives as JAK inhibitors, US201281586162012.
38. Ferguson-Smith A.C., Chen Y.F., Newman M.S., et al. Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics 1988, 2(3):203-208.
39. Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO/2010/0856842010.
40. Taylor V, Li H, Singh R, Compositions and methods for inhibition of the JAK pathway. WO/2011/0171782011.
41. Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO/2012/0159722012.
42. Dana R, Chauhan S, Therapeutic compositions for treatment of ocular inflammatory disorders, WO/2009/0890362009.
43. Rouvier E., Luciani M.F., Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993, 177(1):195-200.
44. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Dis 2012, 11(10):763-776.
45. Quiniou C, Chemtob S, Barney S, Allosteramers for TNF receptors and uses. WO/2010/124259 2010.
46. Kaufmann M, Barney S, Methods of identification of allosteramers. WO/2010/1242622010.
47. Massingale M.L., Li X., Vallabhajosyula M., et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009, 28(9):1023-1027.
48. Tzu J.H., Utine C.A., Stern M.E., et al. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea 2012, 31(6):649-654.
49. Anglade E., Yatscoff R., Foster R., et al. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs 2007, 16(10):1525-1540.
50. Mitra A, Valagaleti PR, Natesan S, Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. US2008/0791702008.
51. Schirra F., Seitz B., Knop N., et al. Sex hormones and dry eye. Ophthalmologe 2009, 106(11):988-994.
52. Mostafa S., Seamon V., Azzarolo A.M. Influence of sex hormones and genetic predisposition in Sjogren's syndrome: a new clue to the immunopathogenesis of dry eye disease. Exp Eye Res 2012, 96(1):88-97.
53. Dalton JT, Miller DD, SARMS and method of use thereof. US201077724332010.
54. Dalton JT, Miller DD, Substituted acylanilides and methods of use thereof. US201180806822011.
55. Dalton JT, Miller DD, Rakov I, et al., Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. US201181105622011.
56. Dalton JT, Barrett C, He Y, et al., Nuclear receptor binding agents. US201281588282012.
57. Zhi L, Selective androgen receptor modulators (SARMS) and uses thereof, WO/2009/082437 2009.
58. Varchi G., Guerrini A., Brigliadori G, et al., Selective androgen receptor modulators (SARMS). WO/2010/0925462010.
59. Varchi G, Tesei A, Brigliadori G, Non-steroidal compounds for androgen receptor modulation. WO/2010/1163422010.
60. Aberg AKG, inventorTreating xerophthalmia with compounds increasing meibomian gland secretion. R-salbutamol for ocular indications is preferably administered by instillation to the eye or into the conjunctival sac. WO/2011/0687862011.
61. Schlienger N, Thygesen MB, Pawlas J, et al., Aminophenyl derivatives as selective androgen receptor modulators. US200975858772009.
62. Ousler III GW, Chapin MJ, Abelson MB, Formulations and methods for treating dry eye. WO/2008/1537462008.
63. Uldam HK, Thygesen MB, N-substituted piperidine derivatives as serotonin receptor agents. WO/2009/0394612009.
64. Schlienger N, Thygesen M, Uldam HK, et al., N-substituted piperidine derivatives as serotonin receptor agents. WO/2010/1113532010.
65. Moulignier A. Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications. Rev Neurol (Paris) 1994, 150(1):3-15.
66. Boullin D.J., Glenton P.A. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine. Br J Pharmacol 1978, 62(4):537-542.
67. Oh U, Cho HW, Yang YD, et al., Method of identifying agents which modulate the activity of calcium activated chloride channel. WO/2009/0514392009.
68. Goyal S., Chauhan S.K., El Annan J., et al. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Arch Ophthalmol 2010, 128(7):819-824.
69. Dana R, Chauhan S, Therapeutic compositions for the treatment of dry eye disease. WO/2011/1066972011.
70. Goyal S., Chauhan S.K., Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol 2012, 130(1):84-89.
71. Aberg AKG, Johnson K, Treating xerophthalmia with Norketotifen. WO/2010/0476812010.
72. Aberg AKG, Johnson K, Ocular formulations of Norketotifen. WO/2010/0598942010.
73. Milner E., Sousa J., Pybus B., et al. Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur J Drug Metab Pharmacokinet 2012, 37(1):17-22.
74. Ramsden N, Major J, Morel A, et al., Pyrimidine derivatives as ZAP-70 inhibitors. WO/2010/1427662010.
75. Major J, Piton N, Sulfonamides and sulfamides as ZAP-70 inhibitors. WO/2010/1461322010.
76. Sunose M, Major J, Harrison RJ, et al., Heterocyclylaminopyrimidines as kinase inhibitors. WO/2010/1461332010.
77. Fischer A., Picard C., Chemin K., et al. ZAP70: a master regulator of adaptive immunity. Semin Immunopathol 2010, 32(2):107-116.
78. Elder M.E. ZAP-70 and defects of T-cell receptor signaling. Semin Hematol 1998, 35(4):310-320.
79. Negishi I., Motoyama N., Nakayama K., et al. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 1995, 376(6539):435-438.
80. Nakajima T, Nakajima T, Azuma M, Partial peptide of lacritin. WO/2011/0342072011.
81. Karnati R., Laurie D.E., Laurie G.W. Lacritin and the tear proteome as natural replacement therapy for dry eye. Exp Eye Res 2013.
82. Cha S, Pauley KM, Targeted receptor-mediated siRNA. WO/2012/0060832012.
83. Michael J. Dart, Philip R. Kym, Eric A. Voight, et al., Trpv1 antagonists. WO20130962262013.
84. Martinez T., Wright N., Lopez-Fraga M., et al. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 2013, 132(5):481-493.
85. V. G., J. M-M, Sádaba B., et al., editors. SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study). ARVO 2012; 2012.
86. Carracedo G., Peral A., Pintor J. Diadenosine polyphosphates in tears of Sjogren syndrome patients. Invest Ophthalmol Vis Sci 2010, 51(11):5452-5459.
87. Pintor J. A molecular marker for dry eye. Archivos de la Sociedad Espanola de Oftalmologia 2007, 82(3):129-130.
88. McGinnigle S., Naroo S.A., Eperjesi F. Evaluation of dry eye. Surv Ophthalmol 2012, 57(4):293-316.
89. Lemp M.A., Bron A.J., Baudouin C., et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011, 151(5). 792-8 e1.